276 related articles for article (PubMed ID: 11711528)
41. The clinical implications of aldosterone escape in congestive heart failure.
Struthers AD
Eur J Heart Fail; 2004 Aug; 6(5):539-45. PubMed ID: 15301999
[TBL] [Abstract][Full Text] [Related]
42. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
43. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
Kalidindi SR; Tang WH; Francis GS
Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):368-78. PubMed ID: 17589427
[TBL] [Abstract][Full Text] [Related]
44. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
Adams KF
Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
[TBL] [Abstract][Full Text] [Related]
45. Eplerenone in the treatment of chronic heart failure.
Krum H; Liew D
Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
[TBL] [Abstract][Full Text] [Related]
46. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction.
Hayashi M; Tsutamoto T; Wada A; Maeda K; Mabuchi N; Tsutsui T; Matsui T; Fujii M; Matsumoto T; Yamamoto T; Horie H; Ohnishi M; Kinoshita M
J Am Coll Cardiol; 2001 Nov; 38(5):1375-82. PubMed ID: 11691511
[TBL] [Abstract][Full Text] [Related]
47. [Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction].
Hayashi M
J Cardiol; 2004 Feb; 43(2):88-91. PubMed ID: 15046031
[TBL] [Abstract][Full Text] [Related]
48. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy.
Gupta A; Schiros CG; Gaddam KK; Aban I; Denney TS; Lloyd SG; Oparil S; Dell'Italia LJ; Calhoun DA; Gupta H
J Hum Hypertens; 2015 Apr; 29(4):241-6. PubMed ID: 25231508
[TBL] [Abstract][Full Text] [Related]
49. Blocking aldosterone in heart failure.
Shafiq MM; Miller AB
Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
[TBL] [Abstract][Full Text] [Related]
50. [The significance of aldosterone in chronic heart failure: the RALES study].
Simko F; Bada V; Simková M; Simko J; Kovács L; Hulín I
Vnitr Lek; 2002 Aug; 48(8):767-72. PubMed ID: 12425209
[TBL] [Abstract][Full Text] [Related]
51. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.
Hayashi M; Tsutamoto T; Wada A; Tsutsui T; Ishii C; Ohno K; Fujii M; Taniguchi A; Hamatani T; Nozato Y; Kataoka K; Morigami N; Ohnishi M; Kinoshita M; Horie M
Circulation; 2003 May; 107(20):2559-65. PubMed ID: 12732605
[TBL] [Abstract][Full Text] [Related]
52. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
Karram T; Abbasi A; Keidar S; Golomb E; Hochberg I; Winaver J; Hoffman A; Abassi Z
Am J Physiol Heart Circ Physiol; 2005 Oct; 289(4):H1351-8. PubMed ID: 15894569
[TBL] [Abstract][Full Text] [Related]
53. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
[TBL] [Abstract][Full Text] [Related]
54. Rationale for the use of aldosterone antagonists in congestive heart failure.
Rocha R; Williams GH
Drugs; 2002; 62(5):723-31. PubMed ID: 11929327
[TBL] [Abstract][Full Text] [Related]
55. [Anti-aldosterone therapy in severe heart failure].
van Guldener C; Donker AJ
Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1724-6. PubMed ID: 10494316
[TBL] [Abstract][Full Text] [Related]
56. [Study of the month. The RALES study (randomized aldactone evaluation study].
Kulbertus H
Rev Med Liege; 1999 Sep; 54(9):770-2. PubMed ID: 10589274
[TBL] [Abstract][Full Text] [Related]
57. [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
Kolloch R; Offers E
MMW Fortschr Med; 2003 Nov; 145(47):42-4, 47. PubMed ID: 14725033
[TBL] [Abstract][Full Text] [Related]
58. High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients.
Sato A; Takane H; Saruta T
Hypertens Res; 2001 Mar; 24(2):99-104. PubMed ID: 11325081
[TBL] [Abstract][Full Text] [Related]
59. The spironolactone renaissance.
Doggrell SA; Brown L
Expert Opin Investig Drugs; 2001 May; 10(5):943-54. PubMed ID: 11322868
[TBL] [Abstract][Full Text] [Related]
60. [Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].
Skvortsov AA; Mareev VIu; Orlova IaA; Chelmakina SM; Baklanova NA; Belenkov IuN
Kardiologiia; 2008; 48(2):52-64. PubMed ID: 18261010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
